Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors

Lignende værker

• Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2
  af: Lee, Weon Sup, et al.
  Udgivet: (2018)
• ACTR-75. A MULTICENTER, 3-ARM, OPEN-LABEL, PHASE IIA CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF TANIBIRUMAB (VEGFR2 MAB), IN PATIENTS WITH RECURRENT GBM ASSESSED WITH K-TRANS AND INITIAL AREA UNDER THE GADOLINIUM CONCENTRATION-TIME CURVE (IAUGC)
  af: Cher, Lawrence, et al.
  Udgivet: (2017)
• The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice
  af: Yoon, Sang Eun, et al.
  Udgivet: (2018)
• The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer
  af: Yoon, Sang Eun, et al.
  Udgivet: (2019)
• Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer
  af: Jung, Ki Sun, et al.
  Udgivet: (2017)